Zhitong Finance App News, Baiyunshan (00874) announced that recently, Guangzhou Baiyunshan Mingxing Pharmaceutical Co., Ltd. (hereinafter referred to as “Mingxing Pharmaceutical”), a wholly-owned subsidiary of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. (hereinafter referred to as “the Company”), received the “Drug Supplement Application Approval Notice” issued by the State Drug Administration. Norepinephrine bitartrate injection (1ml: 2mg) has passed the consistent evaluation of generic drug quality and efficacy.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.